Mankind Pharma

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today

Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.

Chairman and Managing Director of KEI Industries Anil Gupta assumed charge as the Senior V-P, while Sanjay Singhania, managing director and CEO of Epack Prefab Technologies, has been named V-P

Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline

Mankind Pharma on Monday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial for a molecule under development for the treatment of multiple autoimmune disorders. The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia. Developed at the Mankind Research Centre, MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile, the drug firm said in a statement. Arjun Juneja, Chief Operating Officer, Mankind Pharma, said the development of MKP11093 is a major milestone representing the company's endeavour to deliver a best-in-class JAK inhibitor that maximises therapeutic potential while addressing the safety concerns associated with conventional approaches. The Phase 1 trial is expected to begin shortly and will evaluate the safety, tolerability, and ...

Input and finance costs weigh on profitability; chronic, consumer health and BSV acquisition support top line

Mankind Pharma on Thursday reported a 17 per cent decline in consolidated profit after tax (PAT) at Rs 445 crore for the June quarter. The drug maker posted a PAT of Rs 538 crore for the April-June quarter of the last fiscal year. Revenue from operations rose to Rs 3,570 crore for the first quarter as compared to Rs 2,868 crore in the year-ago period, Mankind Pharma said in a statement. The company said its board has approved the raising of up to Rs 1,000 crore through unsecured funding instruments, including issuance of commercial papers, on a private placement basis, in one or more tranches. The board also approved interim dividend of Re 1 per share on face value of Re 1 per share for 2025-26. The company said its board has approved the acquisition of the branded generic business relating to women health portfolio of Bharat Serums and Vaccines Ltd through slump sale on a going concern basis. Shares of the company on Thursday ended 0.28 per cent down at Rs 2,567.75 apiece on the

Shares of Mankind Pharma dropped over 3 per cent after it posted a 10 per cent fall in consolidated net profit Q4 FY25

Strong chronic therapy performance, BSV consolidation drive revenue growth in Q4; net profit declines 10 per cent year-on-year to Rs 425 crore

Stocks to watch today: SBI has reached a housing loan book of Rs 8 trillion and aims to grow its mortgage book to Rs 10 trillion by March 2027, according to its Chairman, C S Setty

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, besides peptides like Glucagon-like peptide-1 (GLP-1)

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

These 15 companies accounted for 70 per cent of total fund mobilisation of Rs 93,453 crore via QIP route in the past six months, according to PRIME Database.

Mankind Pharma share slipped 5.61 per cent at Rs 2,487.15 a piece on the BSE in Friday's intraday trade

Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in Q3FY24

Q3FY25 company results, January 23: Two Adani entities including Adani Energy Solutions and Adani Green Energy will release results for the Oct-Dec quarter today

The pharmaceutical giant criticised the order as 'arbitrary and unjustified,' and confirmed plans to challenge the decision

Stocks to Watch, Jan 8, 2025: From Tata Steel to Dr. Reddy's Labs, here is a list of stocks that will remain in focus today